Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Operating Expenses (2020 - 2024)

Immuneering has reported Operating Expenses over the past 5 years, most recently at $18.6 million for Q4 2024.

  • Quarterly results put Operating Expenses at $18.6 million for Q4 2024, up 13.84% from a year ago — trailing twelve months through Dec 2024 was $64.1 million (up 9.69% YoY), and the annual figure for FY2025 was $59.4 million, down 7.33%.
  • Operating Expenses for Q4 2024 was $18.6 million at Immuneering, up from $15.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for IMRX hit a ceiling of $18.6 million in Q4 2024 and a floor of $3.9 million in Q2 2020.
  • Median Operating Expenses over the past 5 years was $13.2 million (2022), compared with a mean of $11.8 million.
  • Biggest five-year swings in Operating Expenses: surged 116.4% in 2021 and later rose 4.4% in 2024.
  • Immuneering's Operating Expenses stood at $6.0 million in 2020, then surged by 84.12% to $11.1 million in 2021, then grew by 26.01% to $14.0 million in 2022, then grew by 16.56% to $16.3 million in 2023, then increased by 13.84% to $18.6 million in 2024.
  • The last three reported values for Operating Expenses were $18.6 million (Q4 2024), $15.3 million (Q3 2024), and $14.9 million (Q2 2024) per Business Quant data.